Help Bring a New Treatment Option to Patients with Advanced Melanoma

RP1 (vusolimogene oderparepvec ) in combination with nivolumab to treat advanced melanoma is being considered for approval by the FDA for a third time. There is an Advisory Committee meeting scheduled for Thursday, July 30, 2026, for the FDA to hear from interested parties. These meetings give the committee information to help make their decision.

We understand that it is incredibly helpful for patients, families, and caregivers to submit their thoughts in advance of this meeting directly to the FDA. We encourage you to share your story and your request that this treatment for patients with advanced melanoma be approved.

For those of you shared your stories one year ago when we requested you do so, we passed on this information to the FDA over the last year. Whether your situation has changed or not, we hope you will resubmit this time around. It’s important for them to hear current stories. Additionally, this committee is different from those who were involved over the last year.

We recommend respectful and thoughtful communication that urges this treatment’s approval.

Please use the button below to submit your comments by 12:00 PM ET on July 20, 2026.

Thank you for taking the time to share your story and help ensure the voices of the melanoma community are heard.